the pharmaceutical company Astra Zeneca’s report for the second quarter of 2016 came in below analysts’ expectations.
reported earnings per share from core operations was 0:83 dollars, worse than expected 0.86 dollars per share, according to SME Direkt survey.
revenues missed analysts’ expectations of 5.603 billion dollars, compared with the expected $ 5.628 billion.
– We delivered in line with expectations for the first half. It reflected the expecting short-term challenges with outgoing patents, writes Pascal Soriot in the report’s president’s statement.
– Our growth platform continues to grow and it now takes up over 60 percent of our sales. Most importantly, our transformational pipeline that supplies a wide range of different medicines and laying the groundwork for our new growth, he writes on.
The text is updated.
No comments:
Post a Comment